E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bleeding related to benign hysterectomy |
Blødning i relation til benign hysterektomi |
|
E.1.1.1 | Medical condition in easily understood language |
Bleeding related to benign surgical removal of the uterus |
Blødning i forbindelse med godartet kirurgisk fjernelse af livmoderen
|
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066252 |
E.1.2 | Term | Total vaginal hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10046913 |
E.1.2 | Term | Vaginal hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10021152 |
E.1.2 | Term | Hysterectomy (ovaries conserved) |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057318 |
E.1.2 | Term | Total hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059806 |
E.1.2 | Term | Ovariohysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000075 |
E.1.2 | Term | Abdominal hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027801 |
E.1.2 | Term | Modified vaginal hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10023692 |
E.1.2 | Term | Laparoscopically assisted hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10044080 |
E.1.2 | Term | Total abdominal hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042429 |
E.1.2 | Term | Subtotal hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of the study is primarily to investigate Tranexamic acid's impact on preventing perioperative bleeding in benign hysterectomy. This will be investigated both by individual assessment of the intraoperative bleeding in ml, and by using relevant quantitative and qualitative secondary endpoints. The results are also expected to indicate a possible effect of Tranexamic acid on the number of actual intra- and postoperative bleeding complications, and may in this respect be considered as a pilot study. |
Formålet med undersøgelsen er først og fremmest at undersøge Tranexamsyres forebyggende effekt på perioperativ blødning i forbindelse med benigne hysterektomi. Dette vil blive undersøgt både ved individuel vurdering af den peroperative blødning i ml, samt ved hjælp af relevante kvantitative og kvalitative sekundære endpoints. Resultaterne forventes også at indikere en mulig virkning af Tranexamsyre på antallet af reelle per- og postoperative blødningskomplikationer, og kan i denne henseende betragtes som et pilotstudie. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Ikke relevant |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All women above 18 years of age to undergo elective benign hysterectomy during the study period should be invited to participate.
|
Alle kvinder over 18 år som skal have foretaget elektiv benign hysterektomi i forsøgsperioden skal inviteres til at deltage. |
|
E.4 | Principal exclusion criteria |
• Known thrombophilia
• Active / previous thromboembolic disease
• Family history to thromboembolic disease (thrombophilia in the family)
• Hypersensitivity to Tranexamic acid
• Impaired renal function
• Ongoing hematuria
• Subarachnoid hemorrhage
• Daily use of anticoagulant medication
• Preoperative use of Tranexamic acid within 24 hours before surgery
• Known malignancy or hysterectomy as part of the investigation of suspected malignancy
• Insufficient understanding of the information concerning the project
|
•Kendt trombofili
•Aktiv/tidligere tromboembolisk sygdom
•Familiær disposition til tromboembolisk sygdom (trombofili i familien)
•Allergi overfor indholdsstoffet Tranexamsyre
•Nedsat nyrefunktion
•Pågående hæmaturi
•Subarachnoidalblødning
•Daglig brug af antikoagulations medicin
•Præoperativ anvendelse af Tranexamsyre indenfor 24 timer inden operationen
•Kendt malign lidelse eller hysterektomi som del af udredning for mistanke om malign lidelse
•Utilstrækkelig forståelse af informationen vedrørende projektet |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the difference in intraoperative bleeding in benign hysterectomy in the group treated with prophylactic Tranexamic acid compared with placebo. The objective of the study is a 25% reduction of this bleeding.
|
Det primære endpoint er forskellen i den peroperativ blødning ved benign hysterektomi i gruppen behandlet med profylaktisk Tranexamsyre sammenlignet med placebogruppen. Målsætningen i studiet er en 25% reduktion af denne blødning. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The intraoperative bleeding is measured from the start of the operation and to its completion.
|
Den peroperative blødning måles fra operationens start til dennes afslutning. |
|
E.5.2 | Secondary end point(s) |
• The incidence of perioperative bleeding ≥ 1000 ml
• Need for blood transfusion
• Use of trials-independent Tranexamic acid intraoperatively
• Duration of operation
• Incidence of postoperative bleeding complications
• Decrease of hemoglobin - from preoperatively to 4-12 hours postoperatively
• Use of trials independent Tranexamic acid postoperatively (within 24 hours)
• Consumption of pain medication during hospitalization
• Complicating pain condition beyond the expected after hysterectomy
• Number of hospitalization days
• Need for re-operation
• readmissions to a hospital
• Mortality
• Postoperative self-rated health and activity - questionnaire survey |
• Forekomst af peroperative blødninger ≥ 1000 ml
• Behov for blodtransfusion
• Anvendelse af forsøgsuafhængig Tranexamsyre peroperativt
• Operationsvarighed
• Forekomst af postoperative blødningskomplikationer
• Hæmoglobinfald – fra præoperativt til 4-12 timer postoperativt
• Anvendelse af forsøgsuafhængig Tranexamsyre postoperativt (indenfor 24 timer)
• Forbrug af smertestillende medicin under indlæggelsen
• Komplicerende smertetilstand udover det forventelige efter hysterektomi
• Antal indlæggelsesdage
• Behov for re-operation
• Genindlæggelse eller genhenvendelse til hospitalsvæsenet
• Mortalitet
• Postoperativt selvvurderet helbred og aktivitet – spørgeskemaundersøgelse |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Occurence of bleeding ≥ 1000 ml, use of trial-independent Tranexamic acid intraoperatively and duration of surgery is measured from the operatioens start and to its end.
Hemoglobin decrease is measured from 3-0 days preoperatively to 4-12 hours postoperatively.
The use of postoperatively trial-independent Tranexamic acid is observed until 24 hours postoperatively.
Need for blood transfusion and use of painkillers is assessed during the primary hospitalization.
Number of hospitalization days covers the primary hospitalization.
Complicated pain-condition, need for re-operation, readmission to hospital and mortality is all assessed within 30 days postoperatively.
The questionnaire survey will be carried out 30 days after surgery and covers the entire 30-day postoperative period.
|
Forekomst af blødning ≥ 1000 ml, anvendelse af forsøgs uafhængig Tranexamsyre peroperativt og operationsvarighed måles fra operatioens start og til dennes afslutning.
Hæmoglobinfald måles fra 3-0 dage før operationen til 4-12 timer postoperativt.
Anvendelsen af ​​postoperativ forsøgsuafhængig Tranexamsyre observeres indtil 24 timer efter operationen.
Behov for blodtransfusion og brug af smertestillende medicin vurderes under primærindlæggelsen.
Antal indlæggelsesdage dækker over primærindlæggelsen.
Komplicerende smerte-tilstand, behov for re-operation, genindlæggelser/genhendvendelser og mortalitet vurderes alle indenfor 30 dage postoperativt.
Spørgeskemaundersøgelsen vil blive udført 30 dage efter operationen, og omhandler hele den postoperative periode på 30-dage.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial is completed after the last participant has completed the final trials-related activity - the questionnaire survey
|
Forsøget afsluttes efter den sidste forsøgsdeltager har afsluttet den sidste forsøgsrelaterede aktivitet - spørgeskemaundersøgelsen |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |